

**FOOD AND DRUG ADMINISTRATION (FDA)**

Center for Drug Evaluation and Research (CDER)

***Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) Meeting***

Tommy Douglas Conference Center, 10000 New Hampshire Ave, Silver Spring, MD

December 6, 2016

**MEETING ROSTER**

---

---

**ACTING-DESIGNATED FEDERAL OFFICER (Non-Voting)**

**LaToya Bonner, PharmD**

Division of Advisory Committee and Consultant Management

Office of Executive Programs, CDER, FDA

**BONE, REPRODUCTIVE, AND UROLOGIC DRUGS ADVISORY COMMITTEE MEMBERS  
(Voting)**

**Douglas C. Bauer, MD**

Professor of Medicine and Epidemiology &

Biostatistics

University of California, San Francisco

San Francisco, California

**Toby Chai, MD**

Vice Chair of Research

Co-Director of Female Pelvic Medicine and

Reconstructive Surgery Program

Department of Urology

Yale School of Medicine

New Haven, Connecticut

**Kathryn M. Curtis, PhD**

Epidemiologist

Women's Health and Fertility Branch

Division of Reproductive Health

Centers for Disease Control and Prevention

Atlanta, Georgia

**Roger T. Dmochowski, MD**

Professor of Urology

Director, Pelvic Medicine and Reconstruction

Fellowship

Department of Urology

Vanderbilt University Hospital

Nashville, Tennessee

**Matthew T. Drake, MD, PhD**

Associate Professor of Medicine

Chair, Metabolic Bone Disease Core Group

Division of Endocrinology

Mayo Clinic College of Medicine

Rochester, Minnesota

**Vivian Lewis, MD**

*(Chairperson)*

Vice Provost for Faculty Development & Diversity

Professor, Obstetrics and Gynecology

University of Rochester

Rochester, New York

**Stuart S. Howards, MD**

Professor of Urology

Department of Urology

University of Virginia

Charlottesville, Virginia

**Sarah E. Sorscher, JD, MPH**

*(Consumer Representative)*

Researcher

Public Citizen's Health Research Group

Washington, District of Columbia

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) Meeting***  
December 6, 2016

**MEETING ROSTER (cont.)**

---

---

**BONE, REPRODUCTIVE, AND UROLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)**

**Gerard G. Nahum, MD, FACOG**

*(Industry Representative)*

Vice President of Global Development, General  
Medicine  
Women's Healthcare, Long-Acting Contraception,  
Medical Devices, and Special Projects  
Bayer HealthCare Pharmaceuticals, Inc.  
Parsippany, New Jersey

**TEMPORARY MEMBERS (Voting)**

**Robert A. Adler, MD**

Chief, Endocrinology and Metabolism  
Hunter Holmes McGuire Veterans Affairs  
Medical Center  
Professor of Epidemiology and Community Health  
Professor of Internal Medicine  
Medical College of Virginia  
Virginia Commonwealth University  
Richmond, Virginia

**George A. Bishopric**

*(Patient Representative)*  
Fort Lauderdale, Florida

**Diane M. Biskobing, MD**

Professor of Medicine  
Assistant Dean for Advancement of the  
Curriculum  
Medical College of Virginia  
Virginia Commonwealth University  
Richmond, Virginia

**Robert E. Brannigan, MD**

Professor of Urology  
Department of Urology  
Feinburg School of Medicine  
Northwestern University  
Chicago, Illinois

**Glenn D. Braunstein, MD**

Professor of Medicine, Emeritus  
David Geffen School of Medicine  
University of California, Los Angeles  
Chief Medical Officer  
Pathways Genomics  
San Diego, California

**Kenneth Burman, MD**

Chief, Endocrine Section  
Medstar Washington Hospital Center  
Professor, Department of Medicine  
Georgetown University  
Washington, District of Columbia

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) Meeting*  
December 6, 2016

**MEETING ROSTER (cont.)**

---

---

**TEMPORARY MEMBERS (Voting) (cont.)**

**Daniel Gillen, PhD**

Chair and Professor  
Department of Statistics  
University of California, Irvine  
Irvine, California

**Philip Hanno, MD, MPH**

Professor of Urology in Surgery  
Director of Urinary Infection, Inflammation, and  
Interstitial Cystitis  
University of Pennsylvania School of Medicine  
Philadelphia, Pennsylvania

**Kurt McCammon, MD**

Professor, Chairman, and Program Director  
Department of Urology  
Devine Chairman in Genitourinary Reconstructive  
Surgery  
Eastern Virginia Medical School  
Norfolk, Virginia

**Jay Sandlow, MD**

Professor of Urology and Obstetrics/Gynecology  
Vice-Chairman of Urology  
Department of Urology  
Medical College of Wisconsin  
Milwaukee, Wisconsin

**Peter Schlegel, MD**

James J. Colt Professor of Urology  
Professor of Reproductive Medicine  
Weill Cornell Medical College  
Chairman and Urologist-in Chief  
Department of Urology  
New York Presbyterian Hospital  
New York, New York

**Abraham Thomas, MD, MPH**

Senior Vice President and Chair  
Department of Medicine  
New York University Lutheran  
Brooklyn, New York

**Kevin Weinfurt, PhD**

Professor  
Department of Psychiatry and Behavioral Sciences  
Department of Psychology and Neuroscience  
Deputy Director  
Center for Clinical and Genetic Economics  
Duke Clinical Research Institute  
Duke University  
Durham, North Carolina

**FOOD AND DRUG ADMINISTRATION (FDA)**

Center for Drug Evaluation and Research (CDER)

***Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) Meeting***

December 6, 2016

**MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting)**

**Hylton V. Joffe, MD, MMSc**

Director

Division of Bone, Reproductive and Urologic  
Products (DBRUP)

Office of Drug Evaluation III (ODE III)

Office of New Drugs (OND)

CDER, FDA

**Audrey Gassman, MD**

Deputy Director

DBRUP, ODE III, OND, CDER, FDA

**Olivia Easley, MD**

Medical Officer

DBRUP, ODE III, OND, CDER, FDA

**Selena Daniels, PharmD, MS**

Clinical Outcome Assessment Team Leader

Clinical Outcome Assessments Staff

OND, CDER, FDA

**Suresh Kaul, MD, MPH**

Clinical Team Leader

DBRUP, ODE III, OND, CDER, FDA